{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"Krascendo 2","nct_id":"NCT06793215","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krascendo-2-nct06793215. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Krascendo 2","arms":[{"description":"Participants will receive divarasib orally, once daily (QD) and pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W)","label":"Divarasib + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab, pemetrexed and carboplatin or cisplatin via IV infusion Q3W","label":"Pembrolizumab + Pemetrexed + Carboplatin or Cisplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":["Chugai Pharmaceutical"],"completion_date":{"date":"2030-10-31","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer","KRAS G12C Lung Cancer"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Divarasib","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 5 years"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2025-10-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06793215"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krascendo-2-nct06793215"}